Tofacitinib for moderately to severely active ulcerative colitis: A Single Technology Appraisal

Kalita, Neelam, Harris, Petra B, Lord, Joanne, Frampton, Geoffrey, Scott, David A. and Picot, Joanna (2018) Tofacitinib for moderately to severely active ulcerative colitis: A Single Technology Appraisal (Health Technology Assessment, HTA - 17/109/06) Southampton. National Institute for Health and Care Research 232pp.

Record type: Monograph (Project Report)

Abstract

This report is a critique of the company’s submission (CS) to NICE from Pfizer on the clinical effectiveness and cost effectiveness of tofacitinib for moderately to severely active ulcerative colitis. It identifies the strengths and weakness of the CS. Clinical experts were consulted to advise the ERG and to help inform this review.

Text

NICE ERG Report Tofacitinib (26 Oct 2018) - Version of Record

Download (3MB)

Text

Erratum (26 Oct 2018) - Version of Record

Download (1MB)

More information

Published date: 2018

Related URLs:

Identifiers

Local EPrints ID: 437770

URI: http://eprints.soton.ac.uk/id/eprint/437770

PURE UUID: 59f40f19-aa72-4de6-afc9-f20dc34dab21

ORCID for Neelam Kalita:

orcid.org/0000-0002-0973-0160

ORCID for Petra B Harris:

orcid.org/0000-0001-9257-3786

ORCID for Joanne Lord:

orcid.org/0000-0003-1086-1624

ORCID for Geoffrey Frampton:

orcid.org/0000-0003-2005-0497

ORCID for Joanna Picot:

orcid.org/0000-0001-5987-996X

Catalogue record

Date deposited: 14 Feb 2020 17:33

Last modified: 10 Apr 2024 01:50

Export record

Share this record

Share this on Facebook Share this on Twitter Share this on Weibo

Contributors

Author: Neelam Kalita

Author: Petra B Harris

Author: Joanne Lord

Author: Geoffrey Frampton

Author: David A. Scott

Author: Joanna Picot

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Library staff additional information